Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Looks To Deliver On Its Promises In Oncology

Executive Summary

Global Head of Oncology Dave Fredrickson took over the commercial leadership role in October. Now he is overseeing several key growth drivers, including Imfinizi and Lynparza, while building out a new hematology franchise. Fredrickson talked with Scrip about AstraZeneca's oncology strategy at ASCO. 

Advertisement

Related Content

ASCO 2018: Optimism As Industry Resets And Looks To What Is Next
Merck's Keytruda Monotherapy May Get Stuck With Small Role In First-line Lung Cancer
PACIFIC Pays Off Again For AZ With Imfinzi Lung Cancer OS Success
ARCTIC Chill Descends On AstraZeneca's Imfinzi/Treme Combo In NSCLC
Keeping Track: A Fresh Wave Of Approvals
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck
MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC
AstraZeneca Under Soriot: Progress Report

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123302

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel